Marshall Wace, LLP Chimerix Inc Transaction History

Marshall Wace, LLP

$72.2 Billion
Q2 2024

A detailed history of Marshall Wace, LLP transactions in Chimerix Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 156,076 shares of CMRX stock, worth $151,393. This represents 0.0% of its overall portfolio holdings.

Number of Shares

156,076

Holding current value

$151,393

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.87 - $1.05 $135,786 - $163,879	156,076 New	156,076 $137,000
Q2 2022 Aug 15, 2022	BUY	$1.34 - $5.34 $846,290 - $3.37 Million	631,560 New	631,560 $1.31 Million
Q1 2022 May 16, 2022	SELL	$4.58 - $6.8 $652,933 - $969,421	-142,562 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.23 - $7.18 $1.51 Million - $2.07 Million	-288,307 Reduced 66.91%	142,562 $916,000
Q3 2021 Nov 15, 2021	BUY	$5.94 - $8.75 $2.56 Million - $3.77 Million	430,869 New	430,869 $2.67 Million
Q2 2021 Aug 13, 2021	SELL	$7.54 - $9.79 $76,681 - $99,564	-10,170 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.76 - $11.25 $48,409 - $114,412	10,170 New	10,170 $98,000
Q2 2019 Aug 14, 2019	SELL	$2.05 - $4.32 $162,452 - $342,338	-79,245 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$1.79 - $3.12 $141,848 - $247,244	79,245 New	79,245 $166,000

Others Institutions Holding CMRX

# of Institutions

Shares Held

36.8M

Call Options Held

72.2K

Put Options Held

169K

Ra Capital Management, L.P. Boston, MA

8.8M
Shares

$8.54 Million
0.12% of portfolio
Monaco Asset Management Sam

4.38M
Shares

$4.25 Million
0.63% of portfolio
Vanguard Group Inc Valley Forge, PA

4.35M
Shares

$4.22 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

2.22M
Shares

$2.16 Million
0.03% of portfolio
Acadian Asset Management LLC Boston, MA

2.17M
Shares

$2.11 Million
0.01% of portfolio

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account